Eisai to Present New Research on Halaven (Eribulin) at 35th Annual San Antonio Breast Cancer Symposium

Eisai to Present New Research on Halaven (Eribulin) at 35th Annual San Antonio Breast Cancer Symposium PR Newswire HATFIELD, England, November 28, 2012 HATFIELD, England, November 28, 2012 /PRNewswire/ -- For European Medical Media Only Eisai will be presenting six abstracts highlighting new study results for Halaven (eribulin) at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium. The meeting will be held December 4-8, 2012 at the Henry B. Gonzalez Convention Center in San Antonio, Texas. These studies highlight Eisai's current and ongoing clinical research efforts with eribulin, reinforcing the company's commitment to continued research to patients and their families affected by metastatic breast cancer. Additionally, Phase III study results of the head-to-head study of eribulin vs capecitabine will be highlighted as part of a SABCS- sponsored conference to be held on 7 December, 2012. "As part of our human health care mission we strive to better understand the needs of patients and their families to help address unmet medical needs and increase the benefits that healthcare provides," said Kenichi Nomoto, Ph.D., President, Oncology Product Creation Unit at Eisai. "Our continued work to further understand the clinical profile of eribulin underscores our commitment to this important mission.